The store will not work correctly in the case when cookies are disabled.

JavaScript seems to be disabled in your browser.For the best experience on our site, be sure to turn on Javascript in your browser.

ESTRACE Cream 2g Tablet

$120.50

Quick & depend on certifiedustedenra(R) by ELIHAN PHARMA INC.Medically reviewed by:asa2410

ESTRACE Cream 2g Tablet is used as a treatment for vaginal dryness and atrophy (loss of vaginal tissues and fluids). It contains a combination of hormones that help replenish lost fluids. This cream contains a mixture of the female sex hormones estradiol and progesterone which play a crucial role in maintaining a healthy vaginal environment during menopause.

The cream contains the female sex hormones estradiol and progesterone which are known to have estrogenic properties. Estradiol plays a key role in maintaining the vaginal environment, the estradiol in the vaginal secretions helps maintain the vaginal tissues and fluids and progesterone helps prevent atrophy (loss of vaginal tissues and fluids).

Comparative Analysis of ESTRACE Cream Tablet

Item	1g
Composition	The combination of two hormones, estradiol and progesterone, helps maintain the vaginal tissues and fluids in the vagina and improves vaginal dryness, atrophy, and inflammation. It contains estradiol and progesterone, each in combination with estrogen and the hormones each increase the chance of vaginal dryness and inflammation. It also contains the hormones luteinizing hormone and follicle-stimulating hormone
Strength
rip	Yes
Frequency	Weekly
Count	25
Treatment

The content on this page has been supplied to canadianpharmacyworld.com by an independent third party contracted to provide information for our website. Canadianpharmacyworld.com relies on these third parties to create and maintain this information and cannot guarantee the accuracy or reliability of the information that has been provided to us.

The drug information provided here is only a summary and does not contain all the list of possible side effects and drug interactions regarding this medication. Be sure to contact your doctor or pharmacist if you have any specific question or concern. If you have any concerns or questions about this medicine, please leave the following information with your doctor or pharmacist.

Nausea, vomiting, diarrhea, headache, abdominal pain, or vomiting may occur. If any of these effects persist or worsen, seek medical attention immediately.

If you are allergic to ESTRACE Cream or any of the other ingredients of this medicine, then do not take this medicine. An allergic reaction to this medicine is rare but possible. Symptoms of an allergic reaction may include: a rash, itching, swelling, dizziness, trouble breathing.

Media and/or healthcare providers may contact you if you have any questions or concerns about this treatment. ThisFree Range medication is intended for use in adults and children over 12 years of age who are allergic to estradiol or progesterone. This medication does not work for rare conditions such as cystitis or painful menstruation.

Media and healthcare professionals who use this product: Media and healthcare professionals who use this medication: This medication is used to treat conditions in menopause, including breast cancer, high blood pressure, and osteoporosis. ESTRACE Cream contains the female sex hormones estradiol and progesterone that help maintain the vaginal environment during menopause. This cream contains the hormones estradiol and progesterone which are both female sex hormones, two of the hormones that help maintain the vaginal environment during menopause. ESTRACE Cream does not work for conditions like cystitis or painful menstruation. Doctors and healthcare providers recommend ESTRACE Cream for these conditions as it keeps the vaginal tissues and fluids in the vagina and helps prevent atrophy.

Media and healthcare providers who use this medication: This medication is used to treat conditions in menopause, including breast cancer, high blood pressure, and osteoporosis.

Market Overview

The estrogens market is poised for significant growth, driven by several key factors. Estrogen receptor stimulation is expected to hold promise in the broader Hormone Therapy market, with ongoing studies suggesting a 7-10% increased demand for estrogen cream over traditional oestrogens therapy. The estrogen cream market,, is expected to reach USD 1.2 billion by 2023, growing at a Compound Annual Growth Rate (CAGR) of 4.5% from 2023 to 2022, with a CAGR of 6.2% to 2023. Moreover, estradiol concentrations are becoming a significant factor in prostate cancer management, as patients treated with estradiol products have shown increased risk of developing invasive prostate cancer. The estrogen cream market,, is expected to register significant growth in several key regions, including North America, Europe, Asia-Pacific, the Middle East, and Africa. The demand for estradiol cream, particularly estrogen-containing products, is expected to remain strong in certain regions, driven by strategic initiatives by major players, such as Merck & Co., Inc. and Novartis AG. Additionally, the estrogen cream market,, is experiencing significant growth in emerging markets, driven by countries like China, India, and South Korea. The demand for estrogen cream, particularly estradiol, in hormone receptor positive prostate cancer is anticipated to continue to increase, driven by the rising incidence of this disease among men and the increasing prevalence of prostate cancer among women. The market is also experiencing growth in women with hormone receptor positive prostate cancer, particularly in countries such as China. Market Segmentation and Key DriversThe market for estrogen cream is segmented based on type, location, and regions, with estrogen being one of the most popular medications globally. The estradiol market is segmented by severity of growth, CAGR, industry penetration, and C/O purity.

Market Segmentation

The estradiol market is segmented into estoneurea, estradiol containing cream, estradiol norethindrone, estradiol powder, and estradiol bis (roostum) cream.

Market Drivers

Several factors are driving the growth of the estradiol market:

• Oestrogen Products: The creamsthat drives the demand for estrogen products. Estrogen creamsthe cream can be used alone or with other medications, and is expected to be most effective when combined with oestrogen therapy. Estradiol products are used alone or with other medications, and are expected to show significant growth over several years.
• Estradiol Norethindrone: Empowering patients to take control of their hormone levels. This cream is used to encourage the growth of healthy cells in the prostate, and is expected to increase demand.
• Estradiol bis (roostum): Estradiol bis is used for the treatment of prostate cancer. It is a topical cream that is applied directly to the skin. While it can be applied intradysodium, it is less effective than oestrogen products. The price difference between estradiol and estradiol bis is substantial.
• Pharmaceutical Technology Market: Estradiol manufacturers are driving the demand for therapeutic agents. A product that is being tested in clinical trials for its efficacy and safety has been approved for sale in the United States, and is expected to pose significant growth. Market participants are investing in research and development to develop new therapeutic options, but also in development of efficacy and safety. Additionally, the medical device and pharmaceutical companies are investing in new therapeutic areas, driven by the increasing awareness on hormone therapy and the growing incidence of hormone receptor positive cases globally.
• Technological andHealthcare Risks and Benefits: The creamstheinflammation drives the demand for therapeutic agents, and is expected to increase demand. The creamstheinflammatory cycle increases the risk of bone fracture, and the estradiol products are expected to show growth. These factors, however, are factored in the severity of the growth.
• The Pharmaceutical Industry: Estradiol manufacturers are focusing on developing high-quality, bioequivalent, and,, and in particular, for the treatment of endometriosis.

Financial Performance and Growth Trends

Financial growth is driving the demand for estrogen products: The creamsthehigh sales and demand for new therapeutic agents are expected to keep the cost of treatment underdeveloped in the future. The estrogen cream market is expected to grow at a CAGR of 6.

Introduction to Estradiol

Estradiol is a male hormones estrogen used to treat menopausal symptoms in postmenopausal women. It is one of the most commonly used estrogens in the treatment of, a condition character by thinning and irregular menopausal symptoms.

Market Size and Growth

The global market for Estradiol cents, which is a component of the pharmaceutical company, is significant. As of 2023, the market size for Estradiol was valued at approximately USD 3.58 billion. It is expected to reach USD 5.13 billion by 2032, growing at a Compound Annual Growth Rate (CAGR) of 4.20% from 2024 to 2032[3].

Regional Insights

The market for Estradiol is alsoNorth America, includingissorsideal revenue per patient, is expected to reach USD 2.87 billion by 2026, with a CAGR of USD 4.50% from 2024 to 2032[4].

Erectile Dysfunction (ED)

ED is a common condition requiring effective ED treatment, and Erectile Dysfunction is the inability to have or maintain a hard-on enough erections to have a fulfilling sex life. ED can have a variety of causes, and it is commonly identified through certain physical and emotional traits, ranging from mild to severe. It is highly treatable, but like all treatments, it may take several attempts to address the root cause[2][3].

Driving Factors and Trends

Several factors are driving the growth of the Estradiol market:

• Rising Prevalence of Menopausal Symptoms: The global age demographic has increased dramatically, driven by the introduction of men who have reached menopause and the introduction of women who are seeking comfort and sufficient natural access to sexual intercourse[5].
• Growing Awareness and the Growth of Cultural Groups: According to a, an estimated 5% of U. S. menopause patients are classified as being sexually active[5].
• Growing Geriatric Population: The aging population is more susceptible to physical and psychological factors, which can lead to more severe symptoms such as painful erections and difficulty urinating[5].
• Increased Access and Prescription Pricing: Companies like can now sell over-the-counter (OTC) prescriptions to make ends meet, which is becoming a more cost-effective option[5].

Key Market Players

The Estradiol market is dominated by several major pharmaceutical companies:

• Gentiana Pharmaceuticals Ltd.: She is involved in the development of various therapeutic products, including the commercialisation of Estrace and its branded counterpart,[1].
• Novartis: In 2024, it was the largest pharmaceutical company by patients with sales of USD 5.13 billion. It is one of the largest pharmaceutical companies in the world by revenue, with a revenue of around USD 28.6 billion in 2024[3].
• Boehringer-Ingelheim Pharmaceuticals Ltd.: Known for its clinical trials for the treatment of menopausal hormone receptor-positive osteoporosis, which is treated with low-dose estrogen, and is also a major player in the research and development of a number of pharmaceutical products, including Estradiol,[2].
• AstraZeneca: Thecompany is one of the first pharmaceutical companies to offer ED treatment in the U. S., with sales of USD 26.3 billion in 2024[3].
• Actavis: The company is a large pharmaceutical company with a presence in both developed and developing countries, with a sales of USD 30.6 billion in 2024[2].

Regulatory Focus

In 2023, the regulator began look at the market for Estradiol. The focus was to understand the market dynamics and market trends for Estradiol, as well as provide market-share forecasts. The focus on Estradiol was also due to the growth of healthcare trends and the emergence of new therapies and pharmaceutical companies to further market the drug. The focus on Estradiol also resulted in a reduction in the price of the drug, which helped to drive down its price[5].

Background:Pregnancy is an important factor in the development of the reproductive tract and is known to have a negative effect on fertility. Conventional medicine is not the best course of action to control the fertility in women. The World Health Organization (WHO) has classified hormone therapy as "good" or "bad" medicine, whereas there are a number of different treatment options. However, these treatment options are not available in the United States. The purpose of this study is to provide an overview of the pharmacological, medical, and scientific methods of the use of oestrogens for the control of ovulation. We used a single-blinded clinical study with a population of healthy women with a normal ovarian reserve to evaluate the efficacy of estradiol and its metabolites in inducing ovulation. In addition, the pharmacokinetic and pharmacodynamics of the two active substances in the treatment of female infertility were analyzed.

Objectives:The objective of this study was to evaluate the pharmacokinetic and pharmacodynamics of oestradiol and its metabolites in the treatment of ovulation.

Material and methods:The pharmacokinetic study was performed using the bioequivalence of oestradiol and the metabolites of the metabolites of oestradiol. In this study, the bioequivalence of oestradiol and the metabolites of the metabolites of oestradiol were assessed by the bioassay method.